July 1

On July 1, the Food and Drug Administration (FDA) added a warning to multiple gonadotropin-releasing hormone (GnRH) agonists, drugs often used as puberty blockers in gender-confused youth.

The FDA identified six cases where there was a “plausible” link between GnRH agonists and a condition called pseudotumor cerebri, which is caused by elevated fluid pressure in the brain.

According to the FDA, all six cases were identified in biologically female children between the ages of 5 and 12; five of the six were being treated for early puberty, and the sixth was undergoing “transgender care.”

According to the Daily Wire, symptoms included specifically, “visual disturbances, headaches, and vomiting.” In addition, “Other effects GnRH agonists caused were an increase in blood pressure, brain swelling, and abducens neuropathy.”

July 18

On July 18, a clip of Biden's Assistant Secretary for Health Rachel Levine speaking about youth gender affirmation treatment went viral: In the clip, Levine said, “We really want to ... affirm and to support and empower these youths, not to limit their participation in activities ... and even limit their ability to get gender affirmation treatment in their state."

July 25

Less than one month after the FDA issued the warning on puberty blockers, the Biden administration early last week announced a new plan to modify the Affordable Care Act. The plan would remove safeguarding measures that currently prevent children from having easy access to sex change treatments, sorry or, in progressive speak, "gender-affirmation" care.

These treatments include puberty blockers, cross-sex hormones, and surgeries. The proposal applies to Obamacare health plans, Medicaid, and Medicare.

Sources

• FDA Quietly Adds Warning Of Serious Side Effects To Puberty Blockers, Daily Caller

• Biden demands insurance companies cover medical 'gender transition' and abortion, Post Millenial

• ‘Completely Reversible’: FDA Warns Puberty Blockers Cause Vision Loss, Brain Swelling, News Busters

• Risk of pseudotumor cerebri added to labeling for gonadotropin-releasing hormone agonists, ADA

• HHS Announces Proposed Rule to Strengthen Nondiscrimination in Health Care

Related

• Puberty Blockers are Reversible?, It’s Meseidy